Could tweaking a common Parkinson's drug prevent fainting spells?
NCT ID NCT06831500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether changing the ratio of carbidopa to levodopa in standard Parkinson's medication can reduce orthostatic hypotension—a sudden drop in blood pressure when standing that causes dizziness and fainting. Researchers will give 36 patients with Parkinson's disease or multiple system atrophy (parkinsonian type) single doses of the drug at three different ratios and measure their blood pressure response. The main goal is to see if a larger, more definitive trial is even possible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carbidopa/levodopa
What this could lead to
If it works, this could point toward a way to adjust existing Parkinson's medications to reduce dizziness and fainting when standing.
What could go wrong
This is a very early, small feasibility study with only 36 participants. It is designed to see if a larger trial is possible, not to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Hospitalier Universitaire Vaudois
RECRUITINGLausanne, Canton of Vaud, 1012, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier Universitaire Vaudois (CHUV)
RECRUITINGLausanne, Canton of Vaud, 1005, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••